Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
LAROCCA, Alessandra;BOCCADORO, Mario;PALUMBO, AntonioLast
2014-01-01
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
[Published Vsn] Mateos et al - 2014 - Haematologica - Bortezomib cumulative dose.pdf
Accesso riservato
Descrizione: Published version. Mateos MV, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, Boccadoro M, García-Sanz R, Di Raimondo F, Esseltine DL, van de Velde H, Desai A, Londhe A, San Miguel JF, Palumbo A. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. 2014 Jun;99(6):1114-22. doi: 10.3324/haematol.2013.099341. Epub 2014 Apr 24. PMID: 24763402; PMCID: PMC4040917. © 2014 Ferrata Storti Foundation. Available at: https://haematologica.org/article/view/7054 | https://doi.org/10.3324/haematol.2013.099341 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040917/
Tipo di file:
PDF EDITORIALE
Dimensione
682.24 kB
Formato
Adobe PDF
|
682.24 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
